Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

AusCann Cannabis Stocks

AusCann Cannabis Stock (ACNNF)

AusCann is a pharmaceutical company focusing on pre-clinical drug candidate development and production. They focus on cannabinoid drug candidates and are located in Australia.

Is AusCann Cannabis Stock (ACNNF) a strong BUY and HOLD?

ACNNF Fundamental Analysis

Profile

HQ: Perth, Western Australia
Founded: 2013
Symbol: ACNNF (OTC), AC8 (ASX)

FocusStrong 

Producing and selling medical cannabis to patients in Australia, and later the world. They are focused on creating cannabis treatments for pain, plus other conditions.  This is a $9 billion market in Australia alone. Many investors know of them from their relationship (now closed) with Canopy Growth. 

Size: Neutral

Market Cap: $31.6 mil
Enterprise Value: $17.94 mil
Number of Employees: 32

Markets: Neutral

Primary: Initially Australia (and Tasmania), where medical MJ is legal, but adult use is not (nor expected soon). Also Chile, through a partnership

Secondary: MA, CT, PA, and CA in the near future, Canada

Subsidiaries, Interests:
DayaCann (Chile), Yarra Glen Vineyards Holdings, ACN 096 717 458 Pty Ltd, Australian Commercial Wines Pty Ltd.
 

Operations: Neutral

Cultivation: None
Current production: Drug development focusing on their first product, for chronic pain, a dry powder 50:50 ratio of THC:CBD in a hard shell capsule formulation.

Distribution: Initial sales of their capsules are currently being ordered.
Direct sales: Yes

Store networks: Has an agreement with the leading Australian pharmacy API to distribute medical cannabis through nationwide pharmacy networks

Integration/Diversification: 
Vertically integrated: Yes
Horizontally diversified: No

Financials: Weak

Revenue (2019): $671,000
Shares Outstanding (diluted): 317 million
Return on Equity: -18.55%

Management: Neutral

CEO: Nick Woolf
CFO: Quentin Megson
Director: Max Johnston
Director: Bruce McHarrie
Director: Krista Bates

Old CEO Ido Kanyon stepped down in May. Much of the Board also turned over this year. The end of their relationship with Canopy late last year also shifted the directors. There has been a LOT of turnover for AusCann.

Branding: Neutral

Most of their drugs cover anti-convulsion, anti-inflammatory, anti-nausea, glaucoma, pain management, and appetite stimulation areas. They have not branded any of their drug candidates yet as none are approved.

Valuation: Weak

Current share price: $0.095
Price to Sales: 13,190
52 week low/high: $0.067-$0.25
EV/Revenue: 5,600
Price/Book: 1.22

Financing: Strong

AusCann has no debt but is burning cash fast, typical of most pharma companies undergoing drug development. Clinical trials are expensive, and they have over $34 million to pay for the next few (company net assets were reported at $34.37 million). They reported $7 million in losses last fiscal year. 

 

ACNNF Technical Analysis

Should I buy AusCann Cannabis Stock?

Is AusCann Cannabis Stock (ACNNF) a Buy?

Follow Stephen Goldman as he investigates the differences between common momentum-based indicators such as the MACD and KST (Know Sure Thing) while learning how to spot opportunities to buy and sell AusCann.

Remember sound cannabis stock trading strategies include both Fundamental Analysis and Technical Analysis.

52 week Range -
/

Bottom Line: Is AusCann Cannabis Stock (ACNNF) a Buy?

Recommendation: Weak

Is AusCann Cannabis Stock (ACNNF) a Buy?

AusCann is often referred to as having the lead position in the Australian cannabis industry. They used to have Canopy Growth as 10% investors but now Canopy has been replaced by local Australian Merchant Capital.

From a licensing perspective, they are ahead of other competitors in Australia. They can produce, sell import, and export. They may have a strong position if they can deliver on production and distribution. It’s a big unknown.

The company has reported only $671k in revenue for the year ending Dec 2019. This revenue was not based on sales as none of their drug candidates are approved. The drug furthest along is their 1:1 THC: CBD capsule for chronic pain indications. This would be a large market to enter (Pain drugs) but they are still a way away from sales for this drug.

Its price to sales ratio is an astronomical 13,000 and they EV/Revenue is 5,600. We don’t typically see values this high in our analyses (remember lower is better here).

They do have a partnership with Tasmanian Alkaloids Pty Ltd. to distribute medical cannabis in Tasmania. TasAlk produces 40% of the world’s alkaloid raw material and a partnership with DayaCann, the only licensed medicinal cannabis grower in Chile. These deals extend their reach internationally.

For all the reasons above, we rate this stock as Weak. Perhaps in a few more years, their drugs will be closer to approvals and they’ll be closer to revenue. Until then, expect dilution if you’re a shareholder.

For all the reasons above, we rate this stock as Weak but check out our other featured companies for many other winners in the cannabis and hemp industry.

Symbol Name Last Price Change % Change

Little-known Cannabis Beverage Stock Surges 47%

Little-known Cannabis Beverage Stock Surges 47%. This little-known cannabis beverage stock, Rocky Mountain High Brands (RMHB) was ranked #5 by CanninBot last week. But what happened next? Related: Little-known Biotech Stock Up 149% Last week, CanninBot discovered a...

True Leaf Completes Inaugural Cannabis Harvest — Stock Up 28% Today

True Leaf Completes Inaugural Cannabis Harvest -- First batches exceed quality expectations for potency and purity Vernon, British Columbia--(Newsfile Corp. - August 3, 2021) - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLAA) ("True Leaf" or the...

Sundial to Announce Q2 Financial Results

Sundial to Announce Q2 Financial Results -- CALGARY, AB, Aug. 3, 2021 /PRNewswire/ - Sundial Growers (NASDAQ: SNDL) ("Sundial") announced today that it will release its second quarter financial results ended June 30, 2021 after market close on August 12, 2021....

Voyager Digital Acquires Leading Global Cryptocurrency Payment Processing Company, Coinify

The acquisition accelerates Voyager's international expansion and will diversify the company's products and revenue streams. CSE: VYGROTCQX: VYGVFBorse Frankfurt: UCD2 Voyager Digital Acquires Coinify -- NEW YORK, Aug. 2, 2021 /PRNewswire/ - Voyager Digital Ltd....

Cannin’s Best Cannabis Stocks 2021: Reliq Health

Reliq Health Technologies is a global healthcare technology company that specializes in developing innovative solutions for the community care market. The company recently appeared on Cannin's Best Cannabis Stocks for 2021 - but why is Reliq Health a strong buy?...

Little-known Biotech Stock Up 149%

Little-known Biotech Stock Up 149%? This little-known biotech stock, Core One Labs (CLABD) was ranked #1 by CanninBot last week. But what happened next? Last Wednesday, CanninBot discovered a profitable trade opportunity with Vancouver-based Core One Labs (CLABD) when...

Why is GrowGeneration a Strong Buy?

GrowGeneration Corp. retails hydroponic and organic specialty gardening products. If you had taken our advice to buy this cannabis stock last year, you'd be up 462% on your money. Like most other stocks in the cannabis sector, GrowGeneration stock is currently down...

Cannabis Stock Signal Alert: HEXO

Today, Cannin's machine learning algorithm has just received a cannabis stock signal alert for HEXO. But what makes HEXO stock a buy? Related: Hexo: Should You Buy, Sell or Hold this Cannabis Stock? HEXO Corp is an award-winning consumer packaged goods cannabis...

Should You Invest in AphriHelios?

Established in 2019, AphriHelios (formerly known as CannaLeaf Pty Ltd.), cultivates, processes and exports medical cannabis across Africa and internationally. The company is currently undertaking a four-phase implementation process to become the largest vertically...

Cannin’s Top 3 Cannabis Stocks for July

CanninBot ranks 450 cannabis stocks based on the 10 most effective technical indicators giving you a rank you can take to the bank. Based on CanninBot performance last week, we'd like to share Cannin's top 3 cannabis stocks for July. While many of these stocks have...